[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1243352A1 - 一種egfr/her2受體酪氨酸激酶抑制劑在製備治療her2突變癌症藥物中的用途 - Google Patents

一種egfr/her2受體酪氨酸激酶抑制劑在製備治療her2突變癌症藥物中的用途

Info

Publication number
HK1243352A1
HK1243352A1 HK18102974.6A HK18102974A HK1243352A1 HK 1243352 A1 HK1243352 A1 HK 1243352A1 HK 18102974 A HK18102974 A HK 18102974A HK 1243352 A1 HK1243352 A1 HK 1243352A1
Authority
HK
Hong Kong
Prior art keywords
her2
egfr
tyrosine kinase
kinase inhibitor
receptor tyrosine
Prior art date
Application number
HK18102974.6A
Other languages
English (en)
Inventor
鄒建軍
周彩純
黃亞玲
任勝祥
張革
曾曉玲
楊昌永
曹國慶
Original Assignee
江蘇恒瑞醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江蘇恒瑞醫藥股份有限公司 filed Critical 江蘇恒瑞醫藥股份有限公司
Publication of HK1243352A1 publication Critical patent/HK1243352A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18102974.6A 2016-01-28 2018-03-01 一種egfr/her2受體酪氨酸激酶抑制劑在製備治療her2突變癌症藥物中的用途 HK1243352A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610060520 2016-01-28
CN201611129915 2016-12-09
PCT/CN2017/072212 WO2017129094A1 (zh) 2016-01-28 2017-01-23 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途

Publications (1)

Publication Number Publication Date
HK1243352A1 true HK1243352A1 (zh) 2018-07-13

Family

ID=59397437

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18102974.6A HK1243352A1 (zh) 2016-01-28 2018-03-01 一種egfr/her2受體酪氨酸激酶抑制劑在製備治療her2突變癌症藥物中的用途

Country Status (4)

Country Link
CN (2) CN112426424A (zh)
HK (1) HK1243352A1 (zh)
TW (1) TWI734734B (zh)
WO (1) WO2017129094A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109504769B (zh) * 2017-09-15 2022-06-21 益善生物技术股份有限公司 检测her2基因突变的特异性引物、液相芯片试剂盒和方法
CN110314159A (zh) * 2018-07-05 2019-10-11 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂联合治疗肿瘤疾病的用途
CN113116879A (zh) * 2020-01-15 2021-07-16 江苏恒瑞医药股份有限公司 法米替尼联合紫杉类和铂类药物在制备治疗肿瘤疾病的药物中的用途
CN111110676A (zh) * 2020-03-07 2020-05-08 天津医科大学总医院 阿帕替尼及联合cci-779在制备肺癌药物中的应用
CN118576601A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗结肠癌的药物中的用途
CN112451527B (zh) * 2020-12-02 2022-08-16 北京鞍石生物科技有限责任公司 氨基嘧啶类化合物的用途
CN115779089A (zh) * 2022-11-28 2023-03-14 中国医学科学院肿瘤医院 用于治疗或改善雄性癌症及抑制其细胞系的药物的相关应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020639A (zh) * 2009-09-14 2011-04-20 上海恒瑞医药有限公司 6-氨基喹唑啉或3-氰基喹啉类衍生物、其制备方法及其在医药上的应用
CN102675287A (zh) * 2011-03-11 2012-09-19 江苏恒瑞医药股份有限公司 (e)-n-[4-[[3-氯-4-(2-吡啶基甲氧基)苯基]氨基]-3-氰基-7-乙氧基-6-喹啉基]-3-[(2r)-1-甲基吡咯烷-2-基]丙-2-烯酰胺的可药用的盐、其制备方法及其在医药上的应用
CN103987700B (zh) * 2012-03-09 2016-08-31 江苏豪森药业集团有限公司 4-喹唑啉胺类衍生物及其用途
CN103539783A (zh) * 2012-07-12 2014-01-29 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法

Also Published As

Publication number Publication date
CN107708698A (zh) 2018-02-16
TW201726136A (zh) 2017-08-01
CN112426424A (zh) 2021-03-02
WO2017129094A1 (zh) 2017-08-03
TWI734734B (zh) 2021-08-01

Similar Documents

Publication Publication Date Title
HK1243352A1 (zh) 一種egfr/her2受體酪氨酸激酶抑制劑在製備治療her2突變癌症藥物中的用途
IL291000A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for cancer therapy
IL279258B (en) tyrosine kinase inhibitors
EP3524268A4 (en) USE OF A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND A VEGFR INHIBITOR IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CANCERS
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
IL249596B (en) A compound that inhibits protein kinase atr and which compound that inhibits kinase chk1 for use in cancer treatment
HK1250638A1 (zh) 治療egfr突變的癌症的方法
IL250447A0 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors and methods for their preparation
PL3533796T3 (pl) Związek aminopirazolopirymidynowy stosowany jako inhibitor receptora o aktywności kinazy tyrozynowej czynnika neurotroficznego
SG11201607036XA (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
ZA201607425B (en) Pharmaceutical combination comprising a class iii receptor tyrosine kinase inhibitor and the alkylating histone-deacetylase inhibitor fusion molecule edo-s101 together with its use in the treatment of cancer
PL3447051T3 (pl) Sposób otrzymywania inhibitora kinazy tyrozynowej i jego pochodnej
EP3131552A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
EP3102705A4 (en) Method of identifying tyrosine kinase receptor rearrangements in patients
EP3160479A4 (en) Antagonists for interleukin-17 receptor b (il-17rb) and its ligand il-17b for cancer therapy
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
IL253533B (en) Antihistamine for use in the treatment of breast cancer
EP3668517A4 (en) ADENOSIN RECEPTOR ANTAGONIST MICROPARTICLE FORMULATIONS FOR THE TREATMENT OF CANCER
IL252200B (en) A process for the purification of receptor tyrosine kinase inhibitor axl "r 428"
IL245861A0 (en) Use of substances to treat drug-resistant tumors
EP2809325A4 (en) CANCER POLYTHERAPY USES HSP27 INHIBITORS AND EGFR TYROSINE KINASE INHIBITORS OR ANTIFOLATES
EP3131550A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
GB201621472D0 (en) Inhibitors of ataxia-tellangiectasia mutated and rad3-related protein kinase (ATR) for use in methods of treating cancer
TH1601006427A (th) การใช้สารยับยั้งรีเซพเตอร์ไทโรซีนไคเนส (inhibitor of receptor tyrosine kinase) ในการผลิตยาสำหรับบำบัดรักษาเซลล์มะเร็งปอด